vs
STANDARD BIOTOOLS INC.（LAB）与MANNATECH INC（MTEX）财务数据对比。点击上方公司名可切换其他公司
MANNATECH INC的季度营收约是STANDARD BIOTOOLS INC.的1.5倍（$29.2M vs $19.6M），MANNATECH INC净利率更高（6.6% vs -177.4%，领先184.0%），MANNATECH INC同比增速更快（-8.1% vs -11.5%），MANNATECH INC自由现金流更多（$-2.0M vs $-23.1M），过去两年MANNATECH INC的营收复合增速更高（-5.4% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
曼纳泰克是一家公开上市的跨国多层次直销企业，主营膳食补充剂与个人护理产品，由塞缪尔·卡斯特于1993年11月创立，总部位于美国德克萨斯州花丘，股票在纳斯达克挂牌交易。截至2017年，公司共有252名雇员，产品通过约22万名独立销售代理推广销售。
LAB vs MTEX — 直观对比
营收规模更大
MTEX
是对方的1.5倍
$19.6M
营收增速更快
MTEX
高出3.4%
-11.5%
净利率更高
MTEX
高出184.0%
-177.4%
自由现金流更多
MTEX
多$21.1M
$-23.1M
两年增速更快
MTEX
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $29.2M |
| 净利润 | $-34.7M | $1.9M |
| 毛利率 | 48.5% | 76.4% |
| 营业利润率 | -168.5% | 6.9% |
| 净利率 | -177.4% | 6.6% |
| 营收同比 | -11.5% | -8.1% |
| 净利润同比 | -28.8% | 686.6% |
| 每股收益（稀释后） | $-0.09 | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABMTEX
| Q3 25 | $19.6M | $29.2M | ||
| Q2 25 | $21.8M | — | ||
| Q1 25 | $40.8M | $26.6M | ||
| Q4 24 | — | $29.0M | ||
| Q3 24 | $22.1M | $31.7M | ||
| Q2 24 | $22.5M | $27.7M | ||
| Q1 24 | $45.5M | $29.4M | ||
| Q4 23 | $28.2M | $32.7M |
净利润LABMTEX
| Q3 25 | $-34.7M | $1.9M | ||
| Q2 25 | $-33.5M | — | ||
| Q1 25 | $-26.0M | $-1.5M | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | $-26.9M | $-328.0K | ||
| Q2 24 | $-45.7M | $-624.0K | ||
| Q1 24 | $-32.2M | $1.2M | ||
| Q4 23 | $-19.8M | $-1.8M |
毛利率LABMTEX
| Q3 25 | 48.5% | 76.4% | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | 74.3% | ||
| Q4 24 | — | 80.6% | ||
| Q3 24 | 54.9% | 74.5% | ||
| Q2 24 | 46.1% | 77.1% | ||
| Q1 24 | 53.1% | 78.6% | ||
| Q4 23 | 47.6% | 75.4% |
营业利润率LABMTEX
| Q3 25 | -168.5% | 6.9% | ||
| Q2 25 | -118.1% | — | ||
| Q1 25 | -80.8% | -3.1% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | -120.9% | 2.8% | ||
| Q2 24 | -134.5% | -4.1% | ||
| Q1 24 | -132.2% | 2.8% | ||
| Q4 23 | -75.9% | -2.7% |
净利率LABMTEX
| Q3 25 | -177.4% | 6.6% | ||
| Q2 25 | -153.7% | — | ||
| Q1 25 | -63.8% | -5.8% | ||
| Q4 24 | — | 7.8% | ||
| Q3 24 | -122.0% | -1.0% | ||
| Q2 24 | -203.3% | -2.2% | ||
| Q1 24 | -70.6% | 4.0% | ||
| Q4 23 | -70.2% | -5.4% |
每股收益（稀释后）LABMTEX
| Q3 25 | $-0.09 | $1.01 | ||
| Q2 25 | $-0.09 | — | ||
| Q1 25 | $-0.07 | $-0.80 | ||
| Q4 24 | — | $1.19 | ||
| Q3 24 | $-0.07 | $-0.17 | ||
| Q2 24 | $-0.12 | $-0.33 | ||
| Q1 24 | $-0.27 | $0.63 | ||
| Q4 23 | $-0.24 | $-0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $7.1M |
| 总债务越低越好 | — | $2.9M |
| 股东权益账面价值 | $399.7M | $7.0M |
| 总资产 | $539.6M | $33.9M |
| 负债/权益比越低杠杆越低 | — | 0.42× |
8季度趋势，按日历期对齐
现金及短期投资LABMTEX
| Q3 25 | $129.4M | $7.1M | ||
| Q2 25 | $158.6M | — | ||
| Q1 25 | $150.9M | $9.3M | ||
| Q4 24 | — | $11.4M | ||
| Q3 24 | $210.6M | $12.2M | ||
| Q2 24 | $269.8M | $9.2M | ||
| Q1 24 | $287.1M | $7.9M | ||
| Q4 23 | $51.7M | $7.7M |
总债务LABMTEX
| Q3 25 | — | $2.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — | ||
| Q4 23 | $63.5M | — |
股东权益LABMTEX
| Q3 25 | $399.7M | $7.0M | ||
| Q2 25 | $424.5M | — | ||
| Q1 25 | $454.6M | $7.6M | ||
| Q4 24 | — | $8.6M | ||
| Q3 24 | $489.3M | $10.0M | ||
| Q2 24 | $510.3M | $8.2M | ||
| Q1 24 | $577.3M | $10.4M | ||
| Q4 23 | $-148.1M | $10.5M |
总资产LABMTEX
| Q3 25 | $539.6M | $33.9M | ||
| Q2 25 | $557.0M | — | ||
| Q1 25 | $579.6M | $36.7M | ||
| Q4 24 | — | $36.1M | ||
| Q3 24 | $681.5M | $40.6M | ||
| Q2 24 | $708.7M | $39.9M | ||
| Q1 24 | $777.7M | $41.1M | ||
| Q4 23 | $323.1M | $41.2M |
负债/权益比LABMTEX
| Q3 25 | — | 0.42× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — | ||
| Q4 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $-1.3M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | $-2.0M |
| 自由现金流率自由现金流/营收 | -118.1% | -6.8% |
| 资本支出强度资本支出/营收 | 4.5% | 2.4% |
| 现金转化率经营现金流/净利润 | — | -0.68× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | $-1.2M |
8季度趋势，按日历期对齐
经营现金流LABMTEX
| Q3 25 | $-22.2M | $-1.3M | ||
| Q2 25 | $-20.7M | — | ||
| Q1 25 | $-30.3M | $-1.4M | ||
| Q4 24 | — | $-219.0K | ||
| Q3 24 | $-27.9M | $3.3M | ||
| Q2 24 | $-39.0M | $-2.7M | ||
| Q1 24 | $-62.5M | $1.9M | ||
| Q4 23 | $-14.1M | $-1.3M |
自由现金流LABMTEX
| Q3 25 | $-23.1M | $-2.0M | ||
| Q2 25 | $-22.6M | — | ||
| Q1 25 | $-35.3M | $-1.9M | ||
| Q4 24 | — | $-325.0K | ||
| Q3 24 | $-30.1M | $3.0M | ||
| Q2 24 | $-41.0M | $-2.7M | ||
| Q1 24 | $-63.3M | $1.8M | ||
| Q4 23 | $-14.1M | $-1.5M |
自由现金流率LABMTEX
| Q3 25 | -118.1% | -6.8% | ||
| Q2 25 | -103.6% | — | ||
| Q1 25 | -86.6% | -7.0% | ||
| Q4 24 | — | -1.1% | ||
| Q3 24 | -136.4% | 9.5% | ||
| Q2 24 | -182.2% | -9.9% | ||
| Q1 24 | -138.9% | 6.2% | ||
| Q4 23 | -50.2% | -4.7% |
资本支出强度LABMTEX
| Q3 25 | 4.5% | 2.4% | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | 12.4% | 1.8% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | 10.2% | 0.8% | ||
| Q2 24 | 8.6% | 0.3% | ||
| Q1 24 | 1.7% | 0.2% | ||
| Q4 23 | 0.3% | 0.6% |
现金转化率LABMTEX
| Q3 25 | — | -0.68× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.10× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.59× | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
MTEX
暂无分部数据
